SCHEMBL3938388

SCHEMBL3938388

CC(C)(C)OC(=O)N1CCC(Oc2cccc3c2CCN3c2ccc(I)cc2)CC1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 13/20 0.78
KDM1A O60341 1/20 0.53
PDE4B Q07343 3/20 0.43
PDE4D Q08499 3/20 0.43
PDE4A P27815 2/20 0.43
PDE4C Q08493 2/20 0.43
CACNB4 O00305 1/20 0.43
CACNA1A O00555 1/20 0.43
CACNA1G O43497 1/20 0.43
CACNG3 O60359 1/20 0.43
CACNA1F O60840 1/20 0.43
CACNA1H O95180 1/20 0.43
CACNB3 P54284 1/20 0.43
CACNA2D1 P54289 1/20 0.43
CACNG7 P62955 1/20 0.43
CACNA1B Q00975 1/20 0.43
CACNA1D Q01668 1/20 0.43
CACNB1 Q02641 1/20 0.43
CACNG1 Q06432 1/20 0.43
CACNB2 Q08289 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11398454 0.91 GPR119 (0.79) GPR119KDM1APDE4BPDE4DPDE4A
SCHEMBL3928520 0.89 GPR119 (0.77) GPR119KDM1APDE4BPDE4DPDE4A
SCHEMBL4479695 0.89 GPR119 (0.75) GPR119KDM1APDE4BPDE4DPDE4A
SCHEMBL3927488 0.89 GPR119 (0.75) GPR119KDM1APDE4BPDE4DPDE4A
SCHEMBL3933532 0.88 GPR119 (0.74) GPR119KDM1APDE4BPDE4DPDE4A
SCHEMBL3929722 0.88 GPR119 (1.00) GPR119KDM1A
SCHEMBL3940029 0.87 GPR119 (0.78) GPR119
SCHEMBL4492217 0.87 GPR119 (0.73) GPR119KDM1APDE4BPDE4DPDE4A
SCHEMBL3940346 0.87 GPR119 (0.76) GPR119KDM1APDE4BPDE4DPDE4A
SCHEMBL4490826 0.85 GPR119 (0.71) GPR119KDM1APDE4BPDE4DPDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8222261-B2 Chemical compounds GlaxoSmithKline, LLC (US) 2012-07-17 US disclosed
US-20090318477-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC 2009-12-24 US disclosed
EP-2043744-A2 CHEMICAL COMPOUNDS SmithKline Beecham Corporation (US) 2009-04-08 EP disclosed
WO-2008008895-A1 GPR119 AGONISTS FOR THE TREATMENT OF DIABETES AND RELATED DISORDERS SMITHKLINE BEECHAM CORPORATION (US) 2008-01-17 WO disclosed
WO-2008008887-A2 GPR119 AGONISTS FOR TREATING METABOLIC DISORDERS SMITHKLINE BEECHAM CORPORATION (US) 2008-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318477-A1 CHEMICAL COMPOUNDS GPR119, GOT2, SLC5A2 GPR119 1/4885KDM1A 4302/4885PDE4B 929/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.